KRAS and large cell neuroendocrine carcinoma: Other studies are needed to validate these preliminary results, but for the purpose to select candidate LCNEC patients for immunotherapy, the classification of LCNEC in different genomic subtypes (i.e., “NSCLC-like” characterized by TP53 and KRAS/STK11/KEAP1, “SCLC-like” with concurrent TP53 and RB1, and “Carcinoid-like” with MEN1 mutations) could play a very important role [23].